Catalent, Inc. (NYSE:CTLT) Given Consensus Rating of “Hold” by Brokerages

Shares of Catalent, Inc. (NYSE:CTLT) have earned a consensus recommendation of “Hold” from the eleven ratings firms that are currently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating and three have issued a buy rating on the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $55.65.

A number of research firms have weighed in on CTLT. Stephens reaffirmed an “equal weight” rating and set a $63.50 price target on shares of Catalent in a research note on Thursday, April 4th. StockNews.com started coverage on Catalent in a research report on Monday. They issued a “sell” rating on the stock. Barclays boosted their price target on Catalent from $47.00 to $63.00 and gave the company an “equal weight” rating in a research report on Friday, June 28th. Finally, Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $63.50 price objective on shares of Catalent in a research note on Thursday.

Catalent Price Performance

Shares of NYSE:CTLT opened at $58.07 on Friday. The company has a market cap of $10.51 billion, a P/E ratio of -9.52, a P/E/G ratio of 2.36 and a beta of 1.16. The business has a fifty day simple moving average of $55.72 and a 200-day simple moving average of $54.68. Catalent has a 52 week low of $31.80 and a 52 week high of $60.20. The company has a quick ratio of 1.77, a current ratio of 2.51 and a debt-to-equity ratio of 1.37.

Catalent (NYSE:CTLT) last posted its quarterly earnings results on Wednesday, May 8th. The company reported ($0.15) EPS for the quarter, missing the consensus estimate of $0.21 by ($0.36). The business had revenue of $1.07 billion during the quarter, compared to analysts’ expectations of $1.11 billion. Catalent had a negative net margin of 26.61% and a negative return on equity of 2.73%. Equities research analysts forecast that Catalent will post -0.17 EPS for the current year.

Insider Activity

In related news, CFO Matti Masanovich sold 2,993 shares of the firm’s stock in a transaction on Monday, July 8th. The shares were sold at an average price of $56.74, for a total transaction of $169,822.82. Following the completion of the sale, the chief financial officer now directly owns 33,871 shares of the company’s stock, valued at approximately $1,921,840.54. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. In other Catalent news, CFO Matti Masanovich sold 2,993 shares of the firm’s stock in a transaction that occurred on Monday, July 8th. The stock was sold at an average price of $56.74, for a total transaction of $169,822.82. Following the completion of the sale, the chief financial officer now owns 33,871 shares in the company, valued at approximately $1,921,840.54. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Ricky Hopson sold 1,401 shares of the stock in a transaction that occurred on Tuesday, June 4th. The shares were sold at an average price of $54.26, for a total value of $76,018.26. Following the transaction, the insider now owns 20,617 shares of the company’s stock, valued at $1,118,678.42. The disclosure for this sale can be found here. Insiders own 0.31% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the company. Vanguard Group Inc. grew its stake in Catalent by 1.8% during the 3rd quarter. Vanguard Group Inc. now owns 20,468,027 shares of the company’s stock worth $931,909,000 after buying an additional 365,648 shares during the last quarter. Capital World Investors increased its holdings in shares of Catalent by 6.1% in the 4th quarter. Capital World Investors now owns 19,079,994 shares of the company’s stock worth $857,264,000 after acquiring an additional 1,098,474 shares during the period. Nomura Holdings Inc. boosted its stake in Catalent by 149.4% during the 4th quarter. Nomura Holdings Inc. now owns 11,487,342 shares of the company’s stock valued at $516,126,000 after purchasing an additional 6,881,914 shares during the period. Cadian Capital Management LP grew its position in Catalent by 14.3% in the 4th quarter. Cadian Capital Management LP now owns 6,064,384 shares of the company’s stock worth $272,473,000 after purchasing an additional 759,600 shares during the last quarter. Finally, Ameriprise Financial Inc. increased its position in Catalent by 65.9% in the 3rd quarter. Ameriprise Financial Inc. now owns 3,483,494 shares of the company’s stock valued at $158,601,000 after acquiring an additional 1,384,313 shares during the period.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.